^
Association details:
| Biomarker: | CD33 positive |
|---|---|
| Cancer: | Leukemia |
| Drug: | vixtimotamab (AMV564) (CD3 agonist, CD33 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immunodepletion of MDSC by AMV564, a Novel Bivalent Bispecific CD33/CD3 T-Cell Engager ex vivo in MDS and melanoma
Published date:
02/09/2022
Excerpt:
The in vivo activity of AMV564 was assessed in a luciferase-expressing SKM1 CD33+ disseminated leukemia mouse model...In contrast, AMV564 markedly delayed the initial detection of SKM1 cells until 22 days after delivery (Fig 5A). This delay correlated with an extended survival to 45 days in AMV564-treated mice from 30 days in control antibody-treated animals...
DOI:
10.1016/j.ymthe.2022.02.005
